



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Amy K. McNULTY, et

al.

SERIAL NO.:

10/651,820

GROUP ART UNIT:

1615

FILED:

August 29, 2003

EXAMINER:

FOR:

PROTEASE INHIBITOR COMPOSITIONS FOR PREVENTION AND

GTREATMENT OF SKIN CONDITIONS

ATTORNEY DOCKET NO.: 46635/284565

Date: 6/25/04

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the modified Form PTO/SB/08 are enclosed with this submission for consideration by the Examiner.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. 1.97(b), before issuance of a first Office action on the merits. Applicant believes that no fee is due for

U.S. Serial No. 10/651,461 Filed: August 29, 2003

INFORMATION DISCLOSURE STATEMENT

submission and consideration of this paper. The Commissioner is authorized to charge any fees associated with this filing or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,

Elena S. Polovnikova

Patent Agent Reg. No. 52,130

KILPATRICK STOCKTON LLP Suite 2800, 1100 Peachtree Street Atlanta, Georgia 30309-4530 (404) 815-6500

j

PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/651,820 TRANSMITTAL Filing Date August 29, 2003 **FORM** First Named Inventor Amy K. McNulty (to be used for all correspondence after initial filing) Art Unit 1615 **Examiner Name** 46635/284565 Total Number of Pages in This Submission Attorney Docket Number ENCLOSURES (check all that apply) After Allowance Communication to Drawing(s) ☐ Fee Transmittal Form Group Appeal Communication to Board of Licensing-related Papers Fee Attached Appeals and Interferences Petition Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): Form PTO/SB/08 (one Request for Refund sheet) Express Abandonment Request ___ CD, Number of CD(s) _____ 22 publications Information Disclosure Statement Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Elena S. Polovnikova, Reg. No. 52,130 Individual name Signature 25, 2004 Date CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Angela M. Rossi		1-1
Signature	Ungela In. Trasi	Date	4/25/04
` 			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Oracle Brot approved to the control of the particular to the control of the contr			
e for form 1449A/PTO	Complete if Known		
RMATION DISCLOSURE	Application Number	10/651,820	
TEMENT BY APPLICANT	Date Filed:	August 29, 2003	
I EMENT BY ALL EIGHT	First Named Inventor	Amy K. McNulty	
	Group Art Unit	1615	
/			

(use as many sheets as necessary) Examiner Name 46635/284565 Attorney Docket Number Sheet 1 of 1 **U.S. PATENT DOCUMENTS** Name of Patentee or Applicant of Document Number **Publication Date** Pages, Columns, Lines, Where Relevant Cited Document Passages or Relevant Examine MM-DD-YYYY Cite No.1 Number - Kind Code2 (if r Initials Figures Appear known) 12/03/1985 Buckingham 4,556,560 5,091,193 02/25/1992 Enjolras, et al. 04/08/1997 Pichierri 5,618,529 03/27/2001 Rourke, et al. 6,207,596 B1 6,479,060 B1 11/12/2002 Jones, et al. 6.503.524 B1 01/07/2003 Tyrrell, et al. **FOREIGN PATENT DOCUMENTS** Pages, Columns, Foreign Patent Document Lines, Where Name of Patentee or Relevant Examiner Cite No.1 Publication Date Applicant of Cited Country Code3 - Number4 - Kind Code5 (if Passages or Initials* MM-DD-YYYY Document Relevant Figures T⁸ Appear WIPO 07/06/2000 WO 00/38747 10/23/1997 **WIPO** WO 97/38735 WO 99/45973 09/16/1999 **WIPO** 09/16/1999 **WIPO** WO 99/45974 EP 0 958 833 A1 11/24/1999 Europe 07/26/2001 WIPO WO 01/52842 A1 10/06/1993 EP 0 564 307 A1 Europe 02/04/1999 **WIPO** WO 99/05315 WO 01/17564 A2 03/15/2001 **WIPO WIPO** WO 99/46316 09/16/1999 OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite T² Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials * No. number(s), publisher, city and/or country where published. Lunn, et al., "Degradation and Disposal of Some Enzyme Inhibitors," Applied Biochem. Biotech., 48:57-59 (1994) Rao, et al., Alpha-1 antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes, Investigative Dermatol., 105:572-578 (1995) ELESTAB® HP Brochure entitled "Physico-Chemical Properties," pp. 2, 20,28, 36, 37 (undated) Skinvisible® Brochure entitled "Technology/Research/Products, 6 pages (undated) SEPILIFT® DPHP Brochure entitled "Triple firming action for rejuvenation, moisturization and antiage wrinkle prevention," 8 pages (undated) PENTAPHARM PREREGEN® Brochure, 4 pages (undated)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner

Signature

STA